JW Lifescience Corporation
KRX:234080.KS
10940 (KRW) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 206,860.372 | 188,931.165 | 169,816.95 | 183,521.045 | 170,220.779 | 155,230.052 | 143,599.849 | 132,290.405 | 125,950.121 | 111,121.369 | 88,614.187 | 89,090.519 | 84,121.031 |
| Cost of Revenue
| 155,535.347 | 140,810.465 | 120,659.67 | 124,024.143 | 121,616.016 | 115,715.383 | 106,419.77 | 98,011.984 | 95,746.165 | 86,460.215 | 71,882.166 | 72,707.83 | 67,522.715 |
| Gross Profit
| 51,325.025 | 48,120.7 | 49,157.28 | 59,496.902 | 48,604.763 | 39,514.669 | 37,180.079 | 34,278.421 | 30,203.956 | 24,661.155 | 16,732.021 | 16,382.689 | 16,598.316 |
| Gross Profit Ratio
| 0.248 | 0.255 | 0.289 | 0.324 | 0.286 | 0.255 | 0.259 | 0.259 | 0.24 | 0.222 | 0.189 | 0.184 | 0.197 |
| Reseach & Development Expenses
| 5,161.143 | 5,736.694 | 6,241.614 | 5,195.498 | 3,582.738 | 1,248.826 | 399.416 | 664.663 | 398.977 | 342.277 | 395.877 | 378.36 | 384.798 |
| General & Administrative Expenses
| 2,139.263 | 365.383 | 364.673 | 413.298 | 580.433 | 918.711 | 1,017.093 | 938.607 | 1,238.052 | 1,102.596 | 741.254 | 552.882 | 540.804 |
| Selling & Marketing Expenses
| 7,523.313 | 8,396.401 | 7,927.071 | 7,191.095 | 7,506.661 | 6,479.673 | 6,495.646 | 6,232.724 | 5,465.896 | 3,521.705 | 2,878.574 | 2,575.508 | 2,849.482 |
| SG&A
| 15,140.403 | 8,761.784 | 8,291.744 | 7,604.393 | 8,087.094 | 7,398.384 | 7,512.739 | 7,171.331 | 6,703.948 | 4,624.301 | 3,619.828 | 3,128.39 | 3,390.286 |
| Other Expenses
| -161.563 | 6,532.968 | 6,207.212 | 7,246.47 | 7,185.969 | 384.603 | 52.317 | 122.119 | -62.687 | 1,628.61 | 934.91 | 208.195 | 159.508 |
| Operating Expenses
| 20,463.109 | 21,031.446 | 20,740.57 | 20,046.361 | 18,855.801 | 15,973.353 | 13,403.679 | 12,648.107 | 11,547.996 | 10,050.52 | 8,808.955 | 7,628.393 | 7,002.264 |
| Operating Income
| 30,861.916 | 27,089.254 | 28,416.711 | 39,450.54 | 29,748.962 | 23,541.316 | 23,776.401 | 21,630.314 | 18,655.96 | 14,610.634 | 7,923.065 | 8,754.296 | 9,499.863 |
| Operating Income Ratio
| 0.149 | 0.143 | 0.167 | 0.215 | 0.175 | 0.152 | 0.166 | 0.164 | 0.148 | 0.131 | 0.089 | 0.098 | 0.113 |
| Total Other Income Expenses Net
| 1,767.485 | -6,307.409 | -10,129.607 | -16,710.132 | -1,417.728 | -2,230.617 | -2,283.514 | -2,411.518 | -2,641.425 | -2,455.877 | -4,219.879 | -5,201.793 | -6,148.666 |
| Income Before Tax
| 32,629.401 | 20,781.845 | 18,287.103 | 22,740.409 | 28,331.234 | 21,310.7 | 21,492.886 | 19,218.796 | 16,014.535 | 12,154.758 | 3,703.186 | 3,552.503 | 3,447.386 |
| Income Before Tax Ratio
| 0.158 | 0.11 | 0.108 | 0.124 | 0.166 | 0.137 | 0.15 | 0.145 | 0.127 | 0.109 | 0.042 | 0.04 | 0.041 |
| Income Tax Expense
| 5,564.302 | 5,820.578 | 5,373.484 | 5,440.356 | 6,392.795 | 5,489.736 | 4,710.172 | 4,057.188 | 3,150.322 | 2,798.186 | 2,070.567 | 84.556 | 788.851 |
| Net Income
| 28,143.966 | 14,961.267 | 12,913.619 | 17,300.052 | 21,938.439 | 15,820.964 | 16,782.714 | 15,161.609 | 12,864.213 | 9,356.571 | 1,632.619 | 3,467.947 | 2,658.535 |
| Net Income Ratio
| 0.136 | 0.079 | 0.076 | 0.094 | 0.129 | 0.102 | 0.117 | 0.115 | 0.102 | 0.084 | 0.018 | 0.039 | 0.032 |
| EPS
| 1,817.55 | 966.21 | 828.84 | 1,092.55 | 1,385.48 | 999.14 | 530 | 957.5 | 812.5 | 591 | 132.5 | 364.5 | 263.5 |
| EPS Diluted
| 1,817.55 | 966.21 | 828.84 | 1,092.55 | 1,385.48 | 999 | 530 | 957.5 | 812.5 | 591 | 132.5 | 287 | 220 |
| EBITDA
| 46,369.155 | 39,275.801 | 37,565.745 | 46,509.45 | 41,844.756 | 35,032.128 | 34,959.457 | 34,932.705 | 31,214.074 | 28,246.017 | 20,393.02 | 20,180.712 | 20,967.917 |
| EBITDA Ratio
| 0.224 | 0.208 | 0.221 | 0.253 | 0.246 | 0.226 | 0.243 | 0.264 | 0.248 | 0.254 | 0.23 | 0.227 | 0.249 |